Nuveen LLC Makes New Investment in Integra LifeSciences Holdings Corporation $IART

Key Points

• Nuveen LLC invested approximately $5.12 million in Integra LifeSciences Holdings, acquiring 232,742 shares during the first quarter.
• Multiple hedge funds have recently altered their positions in Integra LifeSciences, with 84.78% of its shares owned by institutional investors.
• Analysts have lowered their price targets for Integra LifeSciences, with an average target of $18.63 and a consensus rating of "Reduce" based on varied outlooks from different brokerages.

Nuveen LLC purchased a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 232,742 shares of the life sciences company's stock, valued at approximately $5,118,000. Nuveen LLC owned 0.30% of Integra LifeSciences as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its stake in Integra LifeSciences by 2,418.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of Integra LifeSciences by 170.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after acquiring an additional 901,600 shares during the period. Soleus Capital Management L.P. bought a new position in shares of Integra LifeSciences in the fourth quarter worth $28,940,000. Charles Schwab Investment Management Inc. grew its position in shares of Integra LifeSciences by 9.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,146,921 shares of the life sciences company's stock valued at $25,221,000 after purchasing an additional 99,348 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Integra LifeSciences by 9.9% during the 4th quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock valued at $20,240,000 after purchasing an additional 80,090 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Price Performance

Shares of IART traded up $0.29 during trading hours on Monday, reaching $15.13. 1,189,457 shares of the company's stock traded hands, compared to its average volume of 1,423,225. Integra LifeSciences Holdings Corporation has a 12 month low of $11.06 and a 12 month high of $27.13. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The stock has a market cap of $1.18 billion, a PE ratio of -2.32, a price-to-earnings-growth ratio of 0.85 and a beta of 1.20. The firm's 50 day simple moving average is $13.12 and its 200-day simple moving average is $15.90.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same period last year, the firm posted $0.63 earnings per share. Integra LifeSciences's quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IART shares. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company decreased their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities cut their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average target price of $18.43.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.